ERBB2 and breast cancer: Clinical trials on the efficacy of drugs in HER2-positive breast cancer with brain metastases have only recently been conducted and primarily demonstrate the benefit of tyrosine kinase inhibitors and novel drug conjugates (Müller et al., 2025).